Patents by Inventor Ching-Cheng Wang

Ching-Cheng Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12224348
    Abstract: A semiconductor device structure is provided. The semiconductor device structure includes a plurality of nanowire structures over a channel region of a semiconductor fin structure, a source/drain feature on a source/drain region of the semiconductor fin structure, and a dielectric fin structure spaced apart from the source/drain feature and the semiconductor fin structure. A top surface of the dielectric fin structure is higher than a top surface of a bottommost one of the nanowire structures, and a bottom surface of the dielectric fin structure is lower than a bottom surface of the source/drain feature.
    Type: Grant
    Filed: April 15, 2024
    Date of Patent: February 11, 2025
    Assignee: TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD.
    Inventors: Kuo-Cheng Chiang, Shi-Ning Ju, Ching-Wei Tsai, Kuan-Lun Cheng, Chih-Hao Wang
  • Publication number: 20250030162
    Abstract: The present invention is a reconfigurable antenna, which includes a total reflection part, a partial reflection part, a partial transmission part, and a radiation part stacked in sequence. A resonant cavity is formed between the partial reflection part and the total reflection part. The radiation part is arranged in the resonant cavity. So that the electromagnetic wave radiated by the radiation part is reflected in the resonant cavity. The electromagnetic wave forms constructive interference during the reflection of the resonant cavity. The resonant cavity makes the electromagnetic wave form the same phase electromagnetic wave and radiation penetrating the reflection part. The partial transmission part is regulated to form beam reconstruction conditions, and the same-phase electromagnetic waves are formed into beams and radiated into space by the beam control conditions.
    Type: Application
    Filed: July 19, 2023
    Publication date: January 23, 2025
    Applicant: National Taiwan University
    Inventors: Yi-Cheng LIN, Ching-Mei WANG, Chang-Kai LAI
  • Patent number: 12178804
    Abstract: Provided herein is salts of formula [A][B], wherein [A] is a cation form of a cycloserine compound and [B] is an anion form of a compound of Formula (I), wherein the ratio between the cycloserine compound and the compound of formula (I) ranges from 10:1 to 1:10. The salts described herein have improved properties, including greatly increased stability and decreased hygroscopicity. Also provided herein are methods for treating and/or reducing the risk of a neuropsychiatric disorder and/or a bacterial infectious disease (e.g., tuberculosis), comprising administering a subject in need a composition comprising salts of formula [A][B] described herein.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: December 31, 2024
    Assignee: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tsai-Miao Shih
  • Patent number: 11753400
    Abstract: The present invention relates to compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: each of A, B, C, D, and E, independently, is C, N, N—H, O, S, or absent; is a single bond or a double bond; each of X, Y, and Z, independently, is aryl, heteroaryl, aralkyl, H, or absent; each of L1 and L2, independently, is a moiety selected from O, CH2, C?O, C2-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, —((CH2)n—W)—, wherein n=0, 1, 2, 3, 4, or 5, and W is O or S, or absent; and when L2 is absent, Z is aryl or heteroaryl fused with BC. Also provided in the present invention is a method for inhibiting, treating and/or reducing the risk of a neuropsychiatric disorder, comprising administering a subject in need a composition comprising a compound of Formula (I).
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: September 12, 2023
    Assignee: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Yuan-Ting Hsieh
  • Patent number: 11739046
    Abstract: The present disclosure provides co-crystals of a lithium benzoate compound and a co-former compound of Formula (I) Also provided herein are methods of preparing the co-crystals and uses thereof in treating and/or reducing the risk for neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, bipolar disorders, or neurogenerative disorders).
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: August 29, 2023
    Assignee: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh, Yuan-Chun Lo
  • Patent number: 11731928
    Abstract: Provided are co-crystals of a sodium benzoate compound and a co-former compound of Formula (I) Also provided herein are methods of preparing the co-crystals and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease) or a glucose or lipid metabolic disorder (e.g., obesity, diabetes, hypercholesterolemia, hypertension, or hyperlipidemia).
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: August 22, 2023
    Assignee: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh, Yuan-Chun Lo
  • Publication number: 20230218623
    Abstract: A salt of a neuroceutical and of an acid, wherein the neuroceutical is a substituted benzodiazepine, a substituted benzothiazepine, a substituted pyridopyrimidines or a substituted amino-cyclohexaneacetic acid; and the acid is benzoic acid, nicotinic acid, pantothenic acid and tannic acid. The molar ratio of the neuroceutical and the acid in the salt ranges from about 6:1 to about 1:5. Also disclosed herein are compositions comprising the neuroceutical salt and therapeutic uses thereof for treating a central nervous system (CNS) disorder or a metabolic disorder associated with the CNS disorder.
    Type: Application
    Filed: May 5, 2021
    Publication date: July 13, 2023
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh, Yi-Feng Huang, Hsin-Hsin Yang, Ming-Hong Chien, Han-Yi Hsieh, Wei-Hua Chang
  • Publication number: 20220402888
    Abstract: Novel co-crystal and eutectic crystal of kojic acid and a co-former that are excellent in physical properties are provided. In one aspect, novel co-crystals of kojic acid and a co-former that is maltol or ethyl maltol are provided. In another aspect, novel crystal of a eutectic mixture of kojic acid and a co-former that is selected from the group consisting of, maltol, ethyl maltol, methyl paraben and propyl gallate are provided. Methods for producing the novel co-crystal or eutectic crystal are also described. The novel co-crystals and eutectic crystals may be included in a pharmaceutical composition, a health food product or a medical food product for the treatment and/or prophylaxis of a neuropsychiatric disorder.
    Type: Application
    Filed: July 15, 2022
    Publication date: December 22, 2022
    Applicant: SyneuRx International (Taiwan) Corp.
    Inventors: Guo-Chuan Emil TSAI, Ching-Cheng WANG, Tien-Lan HSIEH
  • Publication number: 20220304962
    Abstract: The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 5.9, 30.2, and 31.2 degrees; or a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 3.7, 5.9, and 26.6 degrees. The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 3.6, 7.5, 26.6, and 29.4 degrees. Also provided herein are methods of preparing the polymorphic forms of sodium benzoate and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease).
    Type: Application
    Filed: June 7, 2022
    Publication date: September 29, 2022
    Applicant: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
  • Publication number: 20220273600
    Abstract: The present invention relates to a composition comprising a lithium salt of an N-substituted glycine compound and a carrier, wherein the lithium salt of the N-substituted glycine compound is of Formula (I): in which R1, R2, and R3 each are independently hydrogen, alkyl, alkenyl, alkynyl, aralkyl, carbocyclyl, aryl, or heteroaryl, or one of R1, R2, and R3 is absent. Also provided in the present invention is a method of mitigating at least one symptom of a neuropsychiatric disorder, comprising administering to a subject in need thereof the lithium salt of an N-substituted glycine compound of Formula (I).
    Type: Application
    Filed: March 21, 2022
    Publication date: September 1, 2022
    Applicant: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Hsun Huang, Han-Yi Hsieh, Jing-Jia Huang, Ching-Cheng Wang
  • Patent number: 11420953
    Abstract: Novel co-crystal and eutectic crystal of kojic acid and a co-former that are excellent in physical properties are provided. In one aspect, novel co-crystals of kojic acid and a co-former that is maltol or ethyl maltol are provided. In another aspect, novel crystal of a eutectic mixture of kojic acid and a co-former that is selected from the group consisting of, maltol, ethyl maltol, methyl paraben and propyl gallate are provided. Methods for producing the novel co-crystal or eutectic crystal are also described. The novel co-crystals and eutectic crystals may be included in a pharmaceutical composition, a health food product or a medical food product for the treatment and/or prophylaxis of a neuropsychiatric disorder.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: August 23, 2022
    Assignee: SYNEURX INTERNATIONAL (TAIWAN) CORP.
    Inventors: Guo-Chuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
  • Patent number: 11369579
    Abstract: The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 5.9, 30.2, and 31.2 degrees; or a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 3.7, 5.9, and 26.6 degrees. The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 3.6, 7.5, 26.6, and 29.4 degrees. Also provided herein are methods of preparing the polymorphic forms of sodium benzoate and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease).
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: June 28, 2022
    Assignee: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
  • Patent number: 11291654
    Abstract: Formulations comprising cycloserine compounds and one or more enteric materials in a solid dosage form, and uses thereof for treating and/or reducing the risk of a neuropsychiatric disorder or tuberculosis.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: April 5, 2022
    Assignee: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Hsin-Hsin Yang, Hsuan-Ang Tsai
  • Patent number: 11278509
    Abstract: The present invention relates to a composition comprising a lithium salt of an N-substituted glycine compound and a carrier, wherein the lithium salt of the N-substituted glycine compound is of Formula (I): in which R1, R2, and R3 each are independently hydrogen, alkyl, alkenyl, alkynyl, aralkyl, carbocyclyl, aryl, or heteroaryl, or one of R1, R2, and R3 is absent. Also provided in the present invention is a method of mitigating at least one symptom of a neuropsychiatric disorder, comprising administering to a subject in need thereof the lithium salt of an N-substituted glycine compound of Formula (I).
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: March 22, 2022
    Assignee: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Hsun Huang, Han-Yi Hsieh, Jing-Jia Huang, Ching-Cheng Wang
  • Publication number: 20220047561
    Abstract: Provided herein is salts of formula [A][B], wherein [A] is a cation form of a cycloserine compound and [B] is an anion form of a compound of Formula (I), wherein the ratio between the cycloserine compound and the compound of formula (I) ranges from 10:1 to 1:10. The salts described herein have improved properties, including greatly increased stability and decreased hygroscopicity. Also provided herein are methods for treating and/or reducing the risk of a neuropsychiatric disorder and/or a bacterial infectious disease (e.g., tuberculosis), comprising administering a subject in need a composition comprising salts of formula [A][B] described herein.
    Type: Application
    Filed: September 12, 2019
    Publication date: February 17, 2022
    Applicant: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tsai-Miao Shih
  • Patent number: 11202791
    Abstract: Compositions (e.g., pharmaceutical compositions, nutraceutical compositions or medical food compositions) comprising tannic acids, particularly tannic acids which are D-amino acid oxidase inhibitor with superior potency, purity and safety profile; and uses thereof for treating CNS disorder and obesity disorders including diabetes, hyperglycemia, hyperlipidemia or hypercholesterolemia.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: December 21, 2021
    Assignee: SYNEURX INTERNATIONAL (TAIWAN) CORP.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh, Yi-Wen Mao
  • Publication number: 20210340094
    Abstract: Provided are co-crystals of a sodium benzoate compound and a co-former compound of Formula (I) Also provided herein are methods of preparing the co-crystals and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease) or a glucose or lipid metabolic disorder (e.g., obesity, diabetes, hypercholesterolemia, hypertension, or hyperlipidemia).
    Type: Application
    Filed: May 3, 2021
    Publication date: November 4, 2021
    Applicant: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh, Yuan-Chun Lo
  • Publication number: 20210214385
    Abstract: Provided herein are potent compounds of Formula (I) and uses thereof for inhibiting the activity of D-amino acid oxidase (DAAO) or treating diseases or disorders associated with DAAO, such as a central nervous system (CNS) disorder, pain, obesity, diabetes, or hyperlipidemia. Also provided in the present disclosure are methods of synthesizing the Formula (I) compounds described herein.
    Type: Application
    Filed: May 29, 2019
    Publication date: July 15, 2021
    Applicant: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil TSAI, Ching-Cheng Wang, Ming-Hong Chien, Tien-Lan Hsieh
  • Publication number: 20210162316
    Abstract: Improved enrichment methods for preparing tannic acid compositions that have superior potency in inhibiting D-amino acid oxidase, and superior purity and safety profiles. The tannic acid compositions (e.g., pharmaceutical compositions, nutraceutical compositions or medical food compositions) can be used for treating CNS disorder and obesity disorders including diabetes, hyperglycemia, hyperlipidemia or hypercholesterolemia.
    Type: Application
    Filed: December 7, 2017
    Publication date: June 3, 2021
    Applicant: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh, Yi-Wen Mao
  • Patent number: 11008277
    Abstract: Provided are co-crystals of a sodium benzoate compound and a co-former compound of Formula (I) Also provided herein are methods of preparing the co-crystals and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease) or a glucose or lipid metabolic disorder (e.g., obesity, diabetes, hypercholesterolemia, hypertension, or hyperlipidemia).
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: May 18, 2021
    Assignee: SYNEURX INTERNATIONAL (TAIWAN) CORP.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh, Yuan-Chun Lo